Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma.

Cao L, Basudan A, Sikora MJ, Bahreini A, Tasdemir N, Levine KM, Jankowitz RC, McAuliffe PF, Dabbs D, Haupt S, Haupt Y, Lucas PC, Lee AV, Oesterreich S, Atkinson JM.

Cancer Lett. 2019 Jun 20. pii: S0304-3835(19)30372-6. doi: 10.1016/j.canlet.2019.06.011. [Epub ahead of print] No abstract available.

PMID:
31229512
2.

EWS-FLI1 low Ewing sarcoma cells demonstrate decreased susceptibility to T-cell-mediated tumor cell apoptosis.

Bailey KM, Julian CM, Klinghoffer AN, Bernard H, Lucas PC, McAllister-Lucas LM.

Oncotarget. 2019 May 21;10(36):3385-3399. doi: 10.18632/oncotarget.26939. eCollection 2019 May 21.

3.

Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast Cancer.

Kim RS, Song N, Gavin PG, Salgado R, Bandos H, Kos Z, Floris G, Eynden GGVD, Badve S, Demaria S, Rastogi P, Fehrenbacher L, Mamounas EP, Swain SM, Lawrence Wickerham D, Costantino JP, Paik S, Wolmark N, Geyer CE, Lucas PC, Pogue-Geile KL.

J Natl Cancer Inst. 2019 Mar 19. pii: djz032. doi: 10.1093/jnci/djz032. [Epub ahead of print]

PMID:
30888406
4.

Targeted mutation detection in breast cancer using MammaSeq™.

Smith NG, Gyanchandani R, Shah OS, Gurda GT, Lucas PC, Hartmaier RJ, Brufsky AM, Puhalla S, Bahreini A, Kota K, Wald AI, Nikiforov YE, Nikiforova MN, Oesterreich S, Lee AV.

Breast Cancer Res. 2019 Feb 8;21(1):22. doi: 10.1186/s13058-019-1102-7.

5.

Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer.

Basudan A, Priedigkeit N, Hartmaier RJ, Sokol ES, Bahreini A, Watters RJ, Boisen MM, Bhargava R, Weiss KR, Karsten MM, Denkert C, Blohmer JU, Leone JP, Hamilton RL, Brufsky AM, Elishaev E, Lucas PC, Lee AV, Oesterreich S.

Mol Cancer Res. 2019 Feb;17(2):457-468. doi: 10.1158/1541-7786.MCR-18-0946. Epub 2018 Oct 24.

PMID:
30355675
6.

CARMA3 Is a Critical Mediator of G Protein-Coupled Receptor and Receptor Tyrosine Kinase-Driven Solid Tumor Pathogenesis.

McAuley JR, Freeman TJ, Ekambaram P, Lucas PC, McAllister-Lucas LM.

Front Immunol. 2018 Aug 15;9:1887. doi: 10.3389/fimmu.2018.01887. eCollection 2018. Review.

7.

Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations.

Pal R, Wei N, Song N, Wu S, Kim RS, Wang Y, Gavin PG, Lucas PC, Srinivasan A, Allegra CJ, Jacobs SA, Paik S, Schmitz JC, Pogue-Geile KL.

PLoS One. 2018 Aug 17;13(8):e0200836. doi: 10.1371/journal.pone.0200836. eCollection 2018.

8.

Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets.

Varešlija D, Priedigkeit N, Fagan A, Purcell S, Cosgrove N, O'Halloran PJ, Ward E, Cocchiglia S, Hartmaier R, Castro CA, Zhu L, Tseng GC, Lucas PC, Puhalla SL, Brufsky AM, Hamilton RL, Mathew A, Leone JP, Basudan A, Hudson L, Dwyer R, Das S, O'Connor DP, Buckley PG, Farrell M, Hill ADK, Oesterreich S, Lee AV, Young LS.

J Natl Cancer Inst. 2019 Apr 1;111(4):388-398. doi: 10.1093/jnci/djy110.

9.

G protein-coupled receptor kinase-2-deficient mice are protected from dextran sodium sulfate-induced acute colitis.

Steury MD, Kang HJ, Lee T, Lucas PC, McCabe LR, Parameswaran N.

Physiol Genomics. 2018 Jun 1;50(6):407-415. doi: 10.1152/physiolgenomics.00006.2018. Epub 2018 Mar 23.

10.

Opening the Door for Immune Oncology Studies in Invasive Lobular Breast Cancer.

Oesterreich S, Lucas PC, McAuliffe PF, Bruno TC, Vignali DAA.

J Natl Cancer Inst. 2018 Jul 1;110(7):696-698. doi: 10.1093/jnci/djy014. No abstract available.

PMID:
29471462
11.

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.

Hartmaier RJ, Trabucco SE, Priedigkeit N, Chung JH, Parachoniak CA, Vanden Borre P, Morley S, Rosenzweig M, Gay LM, Goldberg ME, Suh J, Ali SM, Ross J, Leyland-Jones B, Young B, Williams C, Park B, Tsai M, Haley B, Peguero J, Callahan RD, Sachelarie I, Cho J, Atkinson JM, Bahreini A, Nagle AM, Puhalla SL, Watters RJ, Erdogan-Yildirim Z, Cao L, Oesterreich S, Mathew A, Lucas PC, Davidson NE, Brufsky AM, Frampton GM, Stephens PJ, Chmielecki J, Lee AV.

Ann Oncol. 2018 Apr 1;29(4):872-880. doi: 10.1093/annonc/mdy025.

12.

The CARMA3-Bcl10-MALT1 Signalosome Drives NFκB Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer.

Ekambaram P, Lee JL, Hubel NE, Hu D, Yerneni S, Campbell PG, Pollock N, Klei LR, Concel VJ, Delekta PC, Chinnaiyan AM, Tomlins SA, Rhodes DR, Priedigkeit N, Lee AV, Oesterreich S, McAllister-Lucas LM, Lucas PC.

Cancer Res. 2018 Mar 1;78(5):1225-1240. doi: 10.1158/0008-5472.CAN-17-1089. Epub 2017 Dec 19.

13.

Role of G protein-coupled receptor kinase-6 in Escherichia coli lung infection model in mice.

Lee T, Packiriswamy N, Lee E, Lucas PC, McCabe LR, Parameswaran N.

Physiol Genomics. 2017 Nov 1;49(11):682-689. doi: 10.1152/physiolgenomics.00066.2017. Epub 2017 Sep 22.

14.

Exome-capture RNA sequencing of decade-old breast cancers and matched decalcified bone metastases.

Priedigkeit N, Watters RJ, Lucas PC, Basudan A, Bhargava R, Horne W, Kolls JK, Fang Z, Rosenzweig MQ, Brufsky AM, Weiss KR, Oesterreich S, Lee AV.

JCI Insight. 2017 Sep 7;2(17). pii: 95703. doi: 10.1172/jci.insight.95703. eCollection 2017 Sep 7.

15.

G-protein-coupled receptor kinase-2 is a critical regulator of TNFα signaling in colon epithelial cells.

Steury MD, Lucas PC, McCabe LR, Parameswaran N.

Biochem J. 2017 Jun 27;474(14):2301-2313. doi: 10.1042/BCJ20170093.

16.

Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.

Priedigkeit N, Hartmaier RJ, Chen Y, Vareslija D, Basudan A, Watters RJ, Thomas R, Leone JP, Lucas PC, Bhargava R, Hamilton RL, Chmielecki J, Puhalla SL, Davidson NE, Oesterreich S, Brufsky AM, Young L, Lee AV.

JAMA Oncol. 2017 May 1;3(5):666-671. doi: 10.1001/jamaoncol.2016.5630. Erratum in: JAMA Oncol. 2017 Mar 1;3(3):418.

17.

MALT1 Protease Activation Triggers Acute Disruption of Endothelial Barrier Integrity via CYLD Cleavage.

Klei LR, Hu D, Panek R, Alfano DN, Bridwell RE, Bailey KM, Oravecz-Wilson KI, Concel VJ, Hess EM, Van Beek M, Delekta PC, Gu S, Watkins SC, Ting AT, Gough PJ, Foley KP, Bertin J, McAllister-Lucas LM, Lucas PC.

Cell Rep. 2016 Sep 27;17(1):221-232. doi: 10.1016/j.celrep.2016.08.080.

18.

API2-MALT1 oncoprotein promotes lymphomagenesis via unique program of substrate ubiquitination and proteolysis.

Rosebeck S, Lim MS, Elenitoba-Johnson KS, McAllister-Lucas LM, Lucas PC.

World J Biol Chem. 2016 Feb 26;7(1):128-37. doi: 10.4331/wjbc.v7.i1.128. Review.

19.

Characterizing Molecular Variants and Clinical Utilization of Next-generation Sequencing in Advanced Breast Cancer.

Gurda GT, Ambros T, Nikiforova MN, Nikiforov YE, Lucas PC, Dabbs DJ, Lee AV, Brufsky AM, Puhalla SL, Bhargava R.

Appl Immunohistochem Mol Morphol. 2017 Jul;25(6):392-398. doi: 10.1097/PAI.0000000000000322.

PMID:
26862949
20.

Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.

Wang P, Bahreini A, Gyanchandani R, Lucas PC, Hartmaier RJ, Watters RJ, Jonnalagadda AR, Trejo Bittar HE, Berg A, Hamilton RL, Kurland BF, Weiss KR, Mathew A, Leone JP, Davidson NE, Nikiforova MN, Brufsky AM, Ambros TF, Stern AM, Puhalla SL, Lee AV, Oesterreich S.

Clin Cancer Res. 2016 Mar 1;22(5):1130-7. doi: 10.1158/1078-0432.CCR-15-1534. Epub 2015 Oct 23.

21.

Non-Hematopoietic β-Arrestin1 Confers Protection Against Experimental Colitis.

Lee T, Lee E, Arrollo D, Lucas PC, Parameswaran N.

J Cell Physiol. 2016 May;231(5):992-1000. doi: 10.1002/jcp.25216. Epub 2015 Nov 20.

22.

Protective Role of β-arrestin2 in Colitis Through Modulation of T-cell Activation.

Sharma D, Malik A, Steury MD, Lucas PC, Parameswaran N.

Inflamm Bowel Dis. 2015 Dec;21(12):2766-77. doi: 10.1097/MIB.0000000000000563.

23.

Molecular drivers of lobular carcinoma in situ.

Logan GJ, Dabbs DJ, Lucas PC, Jankowitz RC, Brown DD, Clark BZ, Oesterreich S, McAuliffe PF.

Breast Cancer Res. 2015 Jun 4;17:76. doi: 10.1186/s13058-015-0580-5. Review.

24.

Conversion of the LIMA1 tumour suppressor into an oncogenic LMO-like protein by API2-MALT1 in MALT lymphoma.

Nie Z, Du MQ, McAllister-Lucas LM, Lucas PC, Bailey NG, Hogaboam CM, Lim MS, Elenitoba-Johnson KS.

Nat Commun. 2015 Jan 8;6:5908. doi: 10.1038/ncomms6908.

PMID:
25569716
25.

Bcl10 mediates angiotensin II-induced cardiac damage and electrical remodeling.

Markó L, Henke N, Park JK, Spallek B, Qadri F, Balogh A, Apel IJ, Oravecz-Wilson KI, Choi M, Przybyl L, Binger KJ, Haase N, Wilck N, Heuser A, Fokuhl V, Ruland J, Lucas PC, McAllister-Lucas LM, Luft FC, Dechend R, Müller DN.

Hypertension. 2014 Nov;64(5):1032-9. doi: 10.1161/HYPERTENSIONAHA.114.03900. Epub 2014 Sep 2.

26.

Nonhematopoietic β-Arrestin-1 inhibits inflammation in a murine model of polymicrobial sepsis.

Sharma D, Packiriswamy N, Malik A, Lucas PC, Parameswaran N.

Am J Pathol. 2014 Aug;184(8):2297-309. doi: 10.1016/j.ajpath.2014.05.002. Epub 2014 Jun 17.

27.

The API2-MALT1 fusion exploits TNFR pathway-associated RIP1 ubiquitination to promote oncogenic NF-κB signaling.

Rosebeck S, Rehman AO, Apel IJ, Kohrt D, Appert A, O'Donnell MA, Ting AT, Du MQ, Baens M, Lucas PC, McAllister-Lucas LM.

Oncogene. 2014 May 8;33(19):2520-30. doi: 10.1038/onc.2013.195. Epub 2013 Jun 17.

28.

β-Arrestin-1 deficiency protects mice from experimental colitis.

Lee T, Lee E, Irwin R, Lucas PC, McCabe LR, Parameswaran N.

Am J Pathol. 2013 Apr;182(4):1114-23. doi: 10.1016/j.ajpath.2012.12.025. Epub 2013 Feb 8.

29.

Bcl10 links saturated fat overnutrition with hepatocellular NF-kB activation and insulin resistance.

Van Beek M, Oravecz-Wilson KI, Delekta PC, Gu S, Li X, Jin X, Apel IJ, Konkle KS, Feng Y, Teitelbaum DH, Ruland J, McAllister-Lucas LM, Lucas PC.

Cell Rep. 2012 May 31;1(5):444-52.

30.

MALT1 protease: a new therapeutic target in B lymphoma and beyond?

McAllister-Lucas LM, Baens M, Lucas PC.

Clin Cancer Res. 2011 Nov 1;17(21):6623-31. doi: 10.1158/1078-0432.CCR-11-0467. Epub 2011 Aug 25. Review.

31.

From MALT lymphoma to the CBM signalosome: three decades of discovery.

Rosebeck S, Rehman AO, Lucas PC, McAllister-Lucas LM.

Cell Cycle. 2011 Aug 1;10(15):2485-96. Epub 2011 Aug 1. Review.

32.

Protease activity of the API2-MALT1 fusion oncoprotein in MALT lymphoma development and treatment.

Rosebeck S, Lucas PC, McAllister-Lucas LM.

Future Oncol. 2011 May;7(5):613-7. doi: 10.2217/fon.11.35. Review.

33.

Use of enterally delivered angiotensin II type Ia receptor antagonists to reduce the severity of colitis.

Okawada M, Koga H, Larsen SD, Showalter HD, Turbiak AJ, Jin X, Lucas PC, Lipka E, Hillfinger J, Kim JS, Teitelbaum DH.

Dig Dis Sci. 2011 Sep;56(9):2553-65. doi: 10.1007/s10620-011-1651-9. Epub 2011 Mar 12.

34.

Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation.

Rosebeck S, Madden L, Jin X, Gu S, Apel IJ, Appert A, Hamoudi RA, Noels H, Sagaert X, Van Loo P, Baens M, Du MQ, Lucas PC, McAllister-Lucas LM.

Science. 2011 Jan 28;331(6016):468-72. doi: 10.1126/science.1198946. Erratum in: Science. 2011 Apr 22;332(6028):421.

35.

Thrombin-dependent NF-{kappa}B activation and monocyte/endothelial adhesion are mediated by the CARMA3·Bcl10·MALT1 signalosome.

Delekta PC, Apel IJ, Gu S, Siu K, Hattori Y, McAllister-Lucas LM, Lucas PC.

J Biol Chem. 2010 Dec 31;285(53):41432-42. doi: 10.1074/jbc.M110.158949. Epub 2010 Nov 1.

36.

The CARMA3-Bcl10-MALT1 signalosome promotes angiotensin II-dependent vascular inflammation and atherogenesis.

McAllister-Lucas LM, Jin X, Gu S, Siu K, McDonnell S, Ruland J, Delekta PC, Van Beek M, Lucas PC.

J Biol Chem. 2010 Aug 20;285(34):25880-4. doi: 10.1074/jbc.C110.109421. Epub 2010 Jul 5.

37.

Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder.

Oravecz-Wilson KI, Philips ST, Yilmaz OH, Ames HM, Li L, Crawford BD, Gauvin AM, Lucas PC, Sitwala K, Downing JR, Morrison SJ, Ross TS.

Cancer Cell. 2009 Aug 4;16(2):137-48. doi: 10.1016/j.ccr.2009.06.007.

38.

AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist.

Rhodes DR, Ateeq B, Cao Q, Tomlins SA, Mehra R, Laxman B, Kalyana-Sundaram S, Lonigro RJ, Helgeson BE, Bhojani MS, Rehemtulla A, Kleer CG, Hayes DF, Lucas PC, Varambally S, Chinnaiyan AM.

Proc Natl Acad Sci U S A. 2009 Jun 23;106(25):10284-9. doi: 10.1073/pnas.0900351106. Epub 2009 Jun 1.

39.

Genetic p53 deficiency partially rescues the adrenocortical dysplasia phenotype at the expense of increased tumorigenesis.

Else T, Trovato A, Kim AC, Wu Y, Ferguson DO, Kuick RD, Lucas PC, Hammer GD.

Cancer Cell. 2009 Jun 2;15(6):465-76. doi: 10.1016/j.ccr.2009.04.011.

40.

Finally, MALT1 is a protease!

McAllister-Lucas LM, Lucas PC.

Nat Immunol. 2008 Mar;9(3):231-3. doi: 10.1038/ni0308-231. No abstract available.

PMID:
18285772
41.

A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-kappaB activation.

Hasegawa M, Fujimoto Y, Lucas PC, Nakano H, Fukase K, Núñez G, Inohara N.

EMBO J. 2008 Jan 23;27(2):373-83. Epub 2007 Dec 13.

42.

Aberrant Huntingtin interacting protein 1 in lymphoid malignancies.

Bradley SV, Smith MR, Hyun TS, Lucas PC, Li L, Antonuk D, Joshi I, Jin F, Ross TS.

Cancer Res. 2007 Sep 15;67(18):8923-31.

43.

A dual role for the API2 moiety in API2-MALT1-dependent NF-kappaB activation: heterotypic oligomerization and TRAF2 recruitment.

Lucas PC, Kuffa P, Gu S, Kohrt D, Kim DS, Siu K, Jin X, Swenson J, McAllister-Lucas LM.

Oncogene. 2007 Aug 16;26(38):5643-54. Epub 2007 Mar 5.

PMID:
17334391
44.

CARMA3/Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells.

McAllister-Lucas LM, Ruland J, Siu K, Jin X, Gu S, Kim DS, Kuffa P, Kohrt D, Mak TW, Nuñez G, Lucas PC.

Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):139-44. Epub 2006 Nov 13.

45.

Clinicopathologic features associated with having four or more metastatic axillary nodes in breast cancer patients with a positive sentinel lymph node.

Rivers AK, Griffith KA, Hunt KK, Degnim AC, Sabel MS, Diehl KM, Cimmino VM, Chang AE, Lucas PC, Newman LA.

Ann Surg Oncol. 2006 Jan;13(1):36-44. Epub 2006 Jan 1.

46.

Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram.

Degnim AC, Reynolds C, Pantvaidya G, Zakaria S, Hoskin T, Barnes S, Roberts MV, Lucas PC, Oh K, Koker M, Sabel MS, Newman LA.

Am J Surg. 2005 Oct;190(4):543-50.

PMID:
16164917
47.

Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease.

Williams J, Lucas PC, Griffith KA, Choi M, Fogoros S, Hu YY, Liu JR.

Gynecol Oncol. 2005 Feb;96(2):287-95.

PMID:
15661210
48.

Wnt10b inhibits development of white and brown adipose tissues.

Longo KA, Wright WS, Kang S, Gerin I, Chiang SH, Lucas PC, Opp MR, MacDougald OA.

J Biol Chem. 2004 Aug 20;279(34):35503-9. Epub 2004 Jun 9.

49.

NF-kappaB signaling in lymphocytes: a new cast of characters.

Lucas PC, McAllister-Lucas LM, Nunez G.

J Cell Sci. 2004 Jan 1;117(Pt 1):31-9. Review.

50.

Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients.

Degnim AC, Griffith KA, Sabel MS, Hayes DF, Cimmino VM, Diehl KM, Lucas PC, Snyder ML, Chang AE, Newman LA.

Cancer. 2003 Dec 1;98(11):2307-15.

Supplemental Content

Loading ...
Support Center